Clinical trials: Glaucoma, Open Angle
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma
Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure…
- Trial name
- NCT03365778
- Testing
- Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Wills Eye
Open Angle Glaucoma
Study of Exchange of Travoprost Intraocular Implant
The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04615403
- Testing
- Travoprost
- Where
- 14 sites in United States, Philippines
- Volunteers
- 33 people
- Sponsor
- Glaukos Corporation
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
Performance of the Travoprost Intraocular Implant
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid…
- Trial name
- NCT06582732
- Testing
- Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6
- Where
- Armenia
- Volunteers
- 210 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction
This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on…
- Trial name
- NCT01547598
- Testing
- travoprost ophthalmic solution 0.004%, travoprost 0.004% / timolol 0.5% combination ophthalmic solution, Bimatoprost ophthalmic solution 0.01%
- Where
- Canada
- Volunteers
- 135 people
- Sponsor
- Allergan
Glaucoma
Open Label Extension of LipoLat-CS202
This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.
- Trial name
- NCT02599688
- Testing
- Observation only
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Peregrine Ophthalmic
Glaucoma, Open-Angle, Ocular Hypertension
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
- Trial name
- NCT01489670
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Switzerland
- Volunteers
- 387 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle Glaucoma
Ahmed Glaucoma Valve Surgery With Mitomycin-C
This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed valve implantation. Approximately 100 patients will be enrolled, with half receiving the Mitomycin-C treatment and the other half…
- Conditions
- Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
- Trial name
- AMCT (NCT02805257)
- Testing
- Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
- Where
- 4 sites in United States, China and 2 more
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Ocular Hypertension, Open Angle Glaucoma
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin…
- Trial name
- NCT01937299
- Testing
- Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Travoprost 0.004% ophthalmic solution
- Volunteers
- 307 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
- Trial name
- NCT01978600
- Testing
- Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, Timolol Maleate 0.5%
- Volunteers
- 89 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open Angle, Ocular Hypertension
Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.
- Trial name
- NCT00804648
- Testing
- Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vistakon Pharmaceuticals
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the efficacy and safety of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04944290
- Testing
- Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 447 people
- Sponsor
- Padagis LLC
Glaucoma, Ocular Hypertension
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02167035
- Testing
- Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Cornerstone Health Care, PA
Open Angle Glaucoma, Ocular Hypertension
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
Selective laser trabeculoplasty (SLT) is a well-recognized way to lower eye pressure in treatment of glaucoma. This treatment is performed for 180 degrees or 360 degrees, and studies at academic centers have shown mixed results…
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome
- Trial name
- NCT02628223
- Testing
- Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- Temple University
Primary Open Angle Glaucoma (POAG)
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients with POAG and indicated cataract surgery.
- Trial name
- NCT02434692
- Testing
- ARGOS-IO system
- Where
- 11 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Open Angle Glaucoma
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
The Investigators will compare, in a randomized, prospective, masked and controlled fashion the effect of a non-steroidal anti-inflammatory agent (Acular LS), a corticosteroid (Pred Forte) and a placebo (Refresh Tears) on patient…
- Trial name
- NCT00478036
- Testing
- Acular LS, Pred Forte, Refresh Tears
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Primary Open Angle Glaucoma
The Effects of Caffeinated Coffee on Intraocular Pressure
High intraocular pressure (IOP) is a known risk factor for developing primary open-angle glaucoma (POAG). There is controversy in the literature regarding the degree to which caffeine influences IOP, with some studies reporting…
- Trial name
- NCT01364207
- Testing
- Caffeinated Coffee, Decaffeinated Coffee
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary